Log in to your Inderes Free account to see all free content on this page.

Brain+

0.00 DKK

0.00 %

Less than 1K followers

BRAINP

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

0.00 %

+8.33 %

-74.00 %

-74.00 %

-80.88 %

-91.75 %

-99.58 %

-

-99.81 %

Brain+ are a pharmaceutical company. The company specializes in research and development for the treatment of dementia and Alzheimer's. The product portfolio includes, for example, cognitive stimulation therapy. In addition to the main business, service and associated ancillary services are also offered. The business is run with the largest presence in Europe. Brain+ is headquartered in Copenhagen.

Market cap

2.95M DKK

Turnover

5.02K DKK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

29.4.

2026

Annual report '25

30.5.

2026

General meeting '26

28.8.

2026

Interim report Q2'26

All

Press releases

3rd party

ShowingAll content types

Regulatory press release2/13/2026, 3:34 PM

Update on in-court restructuring proceedings - 13 February 2026

Regulatory press release2/4/2026, 4:36 PM

Update on in-court restructuring proceedings - 4 February 2026

Regulatory press release1/27/2026, 12:34 PM

Correction: Update on in-court restructuring proceedings - 27 January 2026

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release1/27/2026, 12:10 PM

Update on in-court restructuring proceedings - 27 January 2026

Regulatory press release1/20/2026, 7:52 PM

Notice of in-court restructuring proceedings of BRAIN+ A/S

Regulatory press release1/20/2026, 9:07 AM

Brain+ is seeking restructuring proceedings

Press release1/8/2026, 9:29 PM

Brain+ Investor Update – December 2025

Press release12/4/2025, 11:46 AM

Brain+ Investor Update - November

Regulatory press release11/19/2025, 11:24 AM

Brain+ A/S updates its financial guidance for 2025

Press release11/6/2025, 2:13 PM

Brain+ investor update — October

Press release10/31/2025, 7:00 AM

BRAIN+ UPDATES ITS COMMUNICATION POLICY AS THE COMPANY MOVES INTO A NEW COMMERCIALISATION PHASE

Regulatory press release10/6/2025, 6:20 AM

Brain+ appoints new Chief Financial Officer

Press release9/24/2025, 6:36 AM

Brain+ launches first Ayla NHS pilot with one of the UK’s largest primary care practices

Press release9/16/2025, 7:21 AM

Brain+ signs agreement with Agincare Homes – the fourth UK care home group to deploy effective dementia therapy with Ayla

Regulatory press release9/15/2025, 9:41 AM

The Chief Financial Officer to transition, replacement search has been initiated

Press release9/4/2025, 9:58 AM

Clinical pilot of Ayla based dementia therapy (CST) improves cognitive outcome by nearly 50% in care home residents

Press release9/2/2025, 7:44 AM

Brain+ expands its agreement with Southcare Homes Group to deploy Ayla across the group

Press release9/1/2025, 6:41 AM

Brain+ invites investors and other stakeholders to a webinar for a presentation of its Half Year 2025 report

Regulatory press release8/28/2025, 9:23 PM

Brain+ publishes Half Year Report for 2025

Regulatory press release6/24/2025, 12:11 PM

Brain+ A/S announces first day of trading in new shares following the TO 5 warrant exercise

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.